Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

First human tests begin for potential new netherton syndrome treatment

NCT ID NCT06539507

Summary

This is an early-stage study to first test the safety of a new drug called BCX17725 in healthy volunteers. It will then test multiple doses in people with Netherton syndrome, a rare genetic skin condition, to see how the body handles the drug and if it helps reduce skin redness, scaling, and itching. The main goal is to find a safe dose and see if the drug shows signs of controlling the disease.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dawes Fretzin Clinical Research Group, LLC

    RECRUITING

    Indianapolis, Indiana, 46250, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Erasmus Universitair Medisch Centrum (EMC)

    RECRUITING

    Rotterdam, 3015 GD, Netherlands

  • Hôpital Saint-Louis

    NOT_YET_RECRUITING

    Paris, 75010, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Maastricht Universitair Medisch Centrum (MUMC+)

    NOT_YET_RECRUITING

    Maastricht, 6229 HX, Netherlands

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Northwestern Dermatology CTU

    RECRUITING

    Chicago, Illinois, 60611, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Nucleus Network

    ACTIVE_NOT_RECRUITING

    Brisbane, Queensland, 4006, Australia

  • Stanford University School of Medicine

    NOT_YET_RECRUITING

    Palo Alto, California, 94304, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Therapeutics Clinical Research

    RECRUITING

    San Diego, California, 92123, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Universitätsklinikum Heidelberg

    NOT_YET_RECRUITING

    Heidelberg, 69120, Germany

  • Veracity Clinical Research

    RECRUITING

    Brisbane, Queensland, 4102, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Westmead Hospital - Department of Dermatology

    RECRUITING

    Sydney, New South Wales, 2145, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Yale Center for Clinical Investigation

    RECRUITING

    New Haven, Connecticut, 06519, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.